U.S. Pharma Onshoring Stocks Retail Investors May Want On Watch

Drug pricing pressure is intensifying in the U.S., yet a quiet shift is also steering more pharmaceutical production back onshore. For investors, that mix of tighter reimbursement and fresh investment in domestic facilities can reshape where value sits in the supply chain. This article walks through three stocks that are directly exposed to the latest policy moves and explains how each could be positioned in this new onshoring story.

The stocks highlighted below are just a sample of this onshoring theme, while the full screen surfaces 39 more U.S. pharma manufacturing and services companies with equally compelling narratives that are not covered here. To identify and analyze your own highest conviction ideas around this trend, head straight into the U.S. Pharma Manufacturing and Onshoring Beneficiaries screener.

Agilent Technologies (A)

Agilent Technologies supplies lab instruments, consumables, software and services that sit behind much of modern drug discovery, diagnostics and manufacturing quality control, which ties it directly to the U.S. pharma manufacturing and onshoring theme. As drugmakers invest more in domestic facilities and tighter testing regimes, Agilent’s chromatography, mass spectrometry and QA/QC workflows are positioned where that capex gets spent. The company is large and diversified with a market cap of about US$43.4b, giving it the scale to support long product cycles and ongoing R&D.

Investors looking at the U.S. onshoring story may find Agilent Technologies interesting because it sells the instruments and software that pharma companies need to prove quality and compliance in new domestic plants, a part of the value chain that can see activity even when drug pricing is under pressure. At the same time, Agilent carries funding and execution risks, including reliance on external financing and a relatively new management team that needs to deliver on margin and growth goals. The onshoring capex and AI driven lab upgrades that management describes, together with the company’s high recurring revenue, strong margins and pharma reshoring exposure, could be more significant for the investment case than the headline valuation alone.

Agilent’s onshoring story is about more than lab hardware. The real question is how its recurring revenue, margins and financing profile all fit together in the current setup. Get the full picture in the Agilent Technologies financial health report

Rapid Micro Biosystems (RPID)

Rapid Micro Biosystems sells automated systems, consumables and software that help drugmakers detect microbial contamination in biomanufacturing and fill finish operations, which fits directly with the U.S. pharma manufacturing and onshoring theme. The company generates its roughly US$35 million of revenue from its Growth Direct platform and related LIMS connection software, consumables and services, and has a market cap of about US$79 million. That places it firmly in the smaller cap end of this onshoring universe, where individual contract wins or setbacks can move the story quickly.

Rapid Micro Biosystems is worth monitoring if you believe stricter U.S. drug pricing will push more volume through highly efficient domestic plants that cannot afford contamination-driven delays. Its Growth Direct platform targets that specific issue for cell and gene therapies, vaccines and sterile injectables. The company remains loss making and depends on customers shifting from trial use to full rollouts to deepen recurring consumable revenue. Cash usage has been significant and upcoming funding needs are an important consideration. A growing installed base, guidance that references continued revenue growth, and a tight focus on microbial quality control provide a clear onshoring-linked thesis for further analysis.

Rapid Micro Biosystems has an onshoring story in which microbial risk control and heavy cash usage pull in opposite directions. The real swing factor is how that balance evolves in the analysis report for Rapid Micro Biosystems

Stevanato Group (STVN)

Stevanato Group designs and supplies the drug containment, delivery and inspection equipment that pharmaceutical companies need for vials, syringes and fill finish lines, which fits closely with the U.S. pharma manufacturing and onshoring theme. Most revenue, about €1.1b, comes from the Biopharmaceutical and Diagnostic Solutions segment, with roughly €253 million from Engineering and a small negative adjustment line. The stock has a market cap of about US$5.7b, putting it in the mid cap bracket among U.S. listed pharma infrastructure peers.

Investors focused on U.S. pharma onshoring should pay attention to Stevanato Group because it sits at the point where drug pricing pressure can translate into higher unit volumes and new capacity for injectable biologics. The company is leaning into high value drug delivery devices and containment for GLP 1s and other biologics, supported by capacity investment and a growing order book. At the same time, relatively modest profitability, reliance on external funding and execution risk in the Engineering segment mean the story is not without pressure points. The key question is whether onshoring driven demand and higher margin devices can offset those risks and turn Stevanato’s current positioning into stronger, more durable earnings power.

Stevanato Group is leaning into higher value drug delivery and containment, yet many investors may be overlooking how future capacity and order visibility link to growth expectations. Get the full context in the analyst forecasts for Stevanato Group

Seeking Alternatives Before The Crowd?

Fresh stock ideas can move quickly once momentum builds and prices start flying. Screen for potential breakouts while they are still under the radar for now, act now.

• Spot emerging leaders with staying power by scanning a curated 75 resilient stocks with low risk scores that aim to keep portfolio swings contained while the market mood keeps shifting.
• Chase real business momentum instead of hype by checking a focused set of 73 profitable AI stocks that aren't just burning cash that already generate cash and fund their own next leg of growth.
• Position ahead of possible demand spikes by reviewing a hand picked group of 38 power grid technology and infrastructure stocks set to benefit if grid upgrades accelerate from here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com